BioSenic SA (BT1)
XFRA 
Summary
BT1 Chart
BioSenic SA (BT1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioSenic SA ever had a stock split?
BioSenic SA Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jean-Luc Vandebroek CEO | XFRA Exchange | BE0974280126 ISIN |
| BE Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BioSenic S.A. is a pioneering biotech company specialized in the development of clinical assets, leveraging advanced technologies in allogeneic cell and gene therapy. With a focus on utilizing bone marrow-sourced mesenchymal stromal cells and Arsenic TriOxide for applications in immuno-oncology and various diseases, BioSenic is at the forefront of innovating treatments for challenging medical conditions. Based in Mont-Saint-Guibert, Belgium, the company is advancing its research and development to address unmet medical needs in graft-versus-host disease (GvHD), systemic lupus erythematosus, and systemic sclerosis, among others. BioSenic’s commitment to developing novel therapies represents a beacon of hope for patients globally.
Products and Services
- Allogeneic Cell and Gene Therapy Platform
This cutting-edge technology focuses on differentiated bone marrow sourced mesenchymal stromal cells. A revolutionary aspect of these therapies is their ability to be stored at the point of use within hospitals, simplifying the logistics and potentially improving the accessibility of treatments for various conditions.
- Arsenic TriOxide Platform
Utilized in immuno-oncology, this platform harnesses Arsenic TriOxide for its potential therapeutic effects. BioSenic is exploring its use in treating a range of conditions including graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. This approach represents a novel avenue in the field of targeted therapies.
- ALLOB
ALLOB is BioSenic’s investigational medicinal product currently in a Phase IIb clinical trial for patients with difficult tibial fractures. This product exemplifies the company’s efforts in advancing bone repair solutions, showcasing their commitment to addressing complex orthopedic problems.
- ArsciCor
Currently in Phase III for treating Graft-versus-Host Disease (GvHD), ArsciCor is being prepared as an oral treatment. This advancement could significantly impact how GvHD is managed, offering a non-invasive treatment option for patients suffering from this condition.
